15/05/2009 (Agence Europe) - On Thursday 14 May 2009, the European Commission cleared the planned creation of a joint biosimilar product venture between pharma companies Lonza (of Switzerland) and Teva (of Israel). Biosimilars are the generic equivalent of drugs produced using biological processes. The Commission concluded that the transaction would not significantly impede effective competition in the European Economic Area (EEA) or any substantial part of it. (L.C./transl.l)